Ιntroduction: The behavioral and psychological symptoms of dementia (BPSD) are still among the most difficult symptoms in
the management of dementia. It is estimated that BPSD affect up to 90% of all dementia subjects over the course of their illness,
and is independently associated with poor outcomes, including distress among patients and caregivers, long-term hospitalization,
early institutionalization, misuse of medication, and increased health care costs. Method: People with Dementia (PwD) and
severe neuropsychiatric symptoms as assessed by the Greek version of Neuropsychiatric Inventory (NPI score >30) were
recruited from the database of the Greek Association of Alzheimer’s disease and Related Disorders. Τhey were assigned to a
prospective experimental study with cannabidiol (CBD) drops (KANNABIO CARE DROPS 3%®). The reassessment was
performed either by a structured telephone interview or by clinical reassessment on site fifteen days after the initiation of the
CBD administration. Results: The follow-up assessment showed improvement of the BPSD in 11 out of 17 of our patients,
as was evaluated by the NPI (a decrease from a mean 65.54 to 19.73) in fifteen days after CBD initiation. These results were
presented regardless of the underlying pathophysiology (Alzheimer’s, Frontotemporal, or Lewy Body Dementia). Conclusion:
Our case series is one of the largest in the current literature regarding cannabinoids and BPSD. We suggest that CBD may be an
effective and safe choice for managing the BPSD. Future clinical trials are needed to reassure these findings.